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OBJECTIVE — Toevaluatetheimpactonglucosemetabolismofalifestyleprogram(theYale
Bright Bodies Program) for obese children.
RESEARCH DESIGN AND METHODS — Thirteen Bright Bodies and ten clinic-care
controlsubjectswhowerepartofalargerandomizedclinicaltrialhad75-goralglucosetolerance
tests at the beginning and end of the 12-month study.
RESULTS — Bright Bodies subjects had signiﬁcantly greater decreases in weight, BMI, and
body fat than clinic-care subjects, and the Bright Body subjects’ changes in body composition
were accompanied by marked improvements in insulin sensitivity (P  0.009) and glucose
tolerance (P  0.04).
CONCLUSIONS — An intensive lifestyle program that successfully reduces body weight
and body fat can markedly improve insulin sensitivity and glucose metabolism in obese youth.
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I
n an attempt to respond to the child-
hood obesity epidemic, we developed
Yale’sBrightBodiesweight-management
program, a family-based lifestyle interven-
tion that includes nutrition education, ex-
ercise, and behavior modiﬁcation. Its
efﬁcacy was validated by a 12-month ran-
domized clinical trial (RCT) with more
than170overweightchildrenandadoles-
cents. In this RCT, Bright Bodies sub-
jects had signiﬁcant improvements in
BMI and body composition, including a
9.2-kg difference in change in total
body fat versus that in the clinic-care
control group (1). To examine the im-
pact of the Bright Bodies program on
insulin sensitivity and glucose metabo-
lism in obese children, a randomly se-
lected subset of subjects from both
groups underwent an oral glucose tol-
erancetest(OGTT)atthebeginningand
end of the 12-month study.
RESEARCH DESIGN AND
METHODS— The Bright Bodies RCT
was approved by the Yale Human Inves-
tigationCommittee.Writteninformedas-
sent and consent were obtained from
participants and parents. Subjects were
recruited from the Yale Pediatric Obesity
Clinic and had to have a BMI at or above
the 95th percentile and be willing to par-
ticipateinaweight-managementprogram
with a parent or caregiver for nutrition
education (if randomized to the interven-
tion group). Subjects were excluded if
they had diabetes, were using a medica-
tion that affects weight or glucose metab-
olism, or had a medical condition that
precluded program participation. Once
randomized 2:1 to either the interven-
tion or control group, 25% of subjects
in each group were randomized to an
OGTT (20 intervention and 14 control
subjects)atbaselineand12months.Thir-
teen intervention and 10 control subjects
completed both OGTTs. Baseline charac-
teristics were similar to those of the gen-
eral RCT and substudy, as were retention
rates.
For the ﬁrst 6 months, children exer-
cised twice per week for 50 min and at-
tendedanutritionorbehavior-modiﬁcation
class for 40 min once per week. To mimic
a maintenance phase, children attended
the program every other week for the
next 6 months. Control subjects were
seen by Yale Pediatric Obesity Clinic
staff every 6 months for follow-up eval-
uation and counseling. Physicians,
nurse practitioners, and registered die-
titians counseled children about im-
provednutritionandactivity,andsocial
workers offered brief psychosocial coun-
seling. Control participants were offered
eligibility to participate in the Bright Bod-
ies program at the end of the study. More
detailed methods have previously been
described (1).
The day before an OGTT, subjects
refrained from strenuous activity, con-
sumed a 250 g carbohydrate diet, and
fasted overnight. Height, weight, BMI,
and body fat were measured using a sta-
diometer and Body Fat Analyzer (Tanita
Corporation, Arlington Heights, IL). A
catheter was inserted into an antecubital
vein for blood sampling. After baseline
samples were obtained for measurement
of fasting plasma glucose and insulin, the
subject drank a ﬂavored glucose drink
(Custom Laboratories, Baltimore, MD)
containing 1.75 g/kg glucose to a maxi-
mum of 75 g. Blood for measurement of
glucoseandinsulinwasobtainedat0,30,
60, 90, 120, and 180 min.
Plasma glucose was measured using a
glucose analyzer (Beckman Instruments
Inc., Fullerton, CA) and insulin by radio-
immunoassay (Linco Laboratories, St.
Charles, MO). Changes in insulin sensi-
tivity were assessed by the whole body
insulinsensitivityindexderivedfromglu-
coseand insulinlevelsduringtheOGTT
(2). The areas under the curve (AUCs)
for insulin (AUCinsulin) and glucose
(AUCglucose) were calculated using the
trapezoidal rule (3). Group comparisons
were made using paired Student’s t tests,
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act test where appropriate.
RESULTS— Except for the signiﬁ-
cantly greater total body fat mass (due to
greater height) of control subjects (P 
0.02), there were no signiﬁcant differ-
ences in baseline characteristics between
the groups (Table 1). As previously re-
ported for the RCT as a whole (1), control
subjects who participated in the OGTT
substudy had signiﬁcant increases in
weight (P  0.003), BMI (P  0.017),
BMIzscore(P0.03),andfatmass(P
0.001) compared with the corresponding
measures in intervention subjects (Table
1). The difference between the two
groups with respect to change in total
body fat was nearly twofold greater than
the differences in change in body weight.
Moreover, increase in weight in the inter-
vention group was fully accounted for by
increases in lean body mass.
Bright Bodies subjects had a 53% re-
duction in AUCinsulin and a 42% increase
in whole body insulin sensitivity index,
whereas the control subjects worsened in
both parameters (P  0.0025 and 0.007,
respectively). These improvements in in-
sulin sensitivity were accompanied by a
small but signiﬁcantly greater decrease in
AUCglucose in the intervention group than
in the control group. It is noteworthy that
fastingand2-hplasmaglucoselevelsnor-
malized in all three intervention subjects
with pre-diabetes (impaired glucose tol-
erance or impaired fasting glucose),
whereas the number of pre-diabetic sub-
jects in the control group increased from
one to ﬁve (P  0.04) after 12 months.
CONCLUSIONS— The aim of this
study was to examine potential metabolic
beneﬁts of a lifestyle and exercise pro-
gram for obese youth without diabetes.
The most striking ﬁnding was that the
BrightBodiesprogramresultedinmarked
improvements in insulin sensitivity and
reductions in glucose-stimulated plasma
insulin and glucose responses. These ob-
servations are important because insulin
resistance and compensatory hyperinsu-
linemia have been suggested to be central
pathophysiologic factors in other clinical
and metabolic complications of obesity,
even in children (4).
Because the changes in body weight
and composition in the subjects ran-
domly selected for this study were nearly
identical in direction and magnitude to
the changes of the intervention and con-
trol groups in the RCT as a whole, it is
reasonable to assume that the metabolic
changes observed in this subset can be
generalizedtothelargergroupofsubjects
in the RCT.
The Diabetes Prevention Program
demonstrated that an intensive lifestyle
program for pre-diabetic adults that re-
sults in sustained weight loss can prevent
or delay the development of type 2 diabe-
tes (5). After the RCT, the reduced rate of
weight gain and improvements in body
compositionseeninthegrowingchildren
comprising the Bright Bodies group re-
stored normal glucose metabolism in the
three subjects with pre-diabetes at base-
line, whereas the prevalence of pre-
diabetes increased from 10 to 50% of
subjectsinthecontrolgroupbytheendof
the study. This ﬁnding is of importance
because obese pre-diabetic children who
continue to gain excessive weight and
body fat rapidly progress to type 2 diabe-
tes (6).
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Table 1—Baseline characteristics and changes after 12 months in the Bright Bodies and control groups
Baseline Change after 12 months
Treatment effect* P Bright Bodies Control P Bright Bodies Control
n 13 10 — 13 10 — —
IFG/IGT† 3 (23) 1 (10) 0.37 0 (0) 5 (50) 0.50 (0.09–0.80)‡ 0.007*
Age (years) 11.3 12.1
Sex (male) 4 (31) 5 (50)
Race/ethnicity
White 4 (31) 5 (50)
Black 5 (38) 3 (30)
Hispanic 4 (31) 2 (20)
Height (cm) 150.79  2.10 160.36  3.41 0.256 4.02  0.75 5.06  0.63 1.04 (3.2 to 1.1) 0.323
Weight (kg) 78.78  7.01 89.96  5.99 0.836 4.18  1.85 11.56  1.12 7.38 (12.6 to 2.9) 0.031*
BMI (kg/m²) 34.08  2.29 34.70  1.72 0.698 0.15  0.67 2.15  0.45 2.00 (4.0 to 0.4) 0.017*
BMI (z score) 2.40  0.1 2.50  0.08 0.387 0.11  0.06 0.06  0.03 0.17 (0.3 to 0.01) 0.034*
Body fat (%) 45.95  2.27 43.79  2.52 0.101 1.82  1.4 7.17  1.6 8.99 (13.6 to 4.3) 0.001*
Lean body mass (kg) 42.42  2.82 55.79  3.35 0.755 4.62  2.1 1.24  1.79 5.86 (0.7 to 13.4) 0.076
Fat mass (kg) 35.53  5.49 43.48  3.13 0.023 0.07  1.26 13.05  1.15 13.12 (17.1 to 9.2) 0.001*
Fasting glucose (mg/dl) 91.8  1.35 91.0  2.33 0.734 1.04  0.89 2.6  2.07 3.64 (7.9 to 0.7) 0.090
Glucose120 (mg/dl) 116.3  5.73 113.3  6.32 0.179 5.54  5.98 9.1  5.82 14.64 (32.4 to 3.1) 0.100
AUCglucose (mg/dl) 121.6  4.81 121.9  6.15 0.754 5.38  4.27 6.61  2.98 11.99 (23.5 to 5.5) 0.042*
Fasting insulin (U/ml) § 30.0 (9.7) 34.0 (19.2) 0.960 4.5 (8.55) 3.0 (8.8) 7.50 (17.0 to 2.0) 0.070
AUCinsulin (U/ml) § 147.1 (111.5) 102.1 (87.6) 0.290 50.9 (84.57) 47.0 (63.9) 97.9 (161.5 to 34.3) 0.003*
WBISI§ 1.51 (0.80) 2.42 (0.70) 0.500 0.63 (0.70) 0.07 (0.58) 0.70 (0.04–1.56) 0.007*
Dataaren,n(%),ormeansSEMofapairedttestunlessotherwiseindicated.*Treatmenteffect:differenceinchangeintheBrightBodiesandcontrolgroups(95%
CI).†PvaluebasedonFisher’sexacttest.‡Differenceinproportions(95%CI)(ref.7).§Wilcoxon’srank-sumtestmedian(interquartilerange)(ref.8).IFG,impaired
fasting glucose; IGT, impaired glucose tolerance; WBISI, whole body insulin sensitivity index.
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